We still don’t know if current vaccines prevent people from transmitting the virus to others. Here’s why that matters in 2021.
Academic rigor, journalistic flair
Articles on COVID-19 vaccines
Displaying 481 - 500 of 576 articles
Here’s what we still need to find out before we can know when we’ll be able to return to our pre-coronavirus ways.
Employers could require their workers to get vaccinated against COVID-19 via both workplace policies and existing laws. Neither option, however, is simple or straightforward.
So, if you have ever tested positive, there is a chance you could contract the virus again. And you could infect other people. You should still take the necessary precautions.
COVID-19 vaccines have very specific storage requirements that make shipping a difficult task. Two ideas – fulfillment centers and cross-docking – could help overcome some distribution challenges.
When allocating resources, we prioritize members of the social groups we belong to, rather than including others in our allocations. This will determine how the COVID-19 vaccine is distributed.
We should applaud drug companies for developing COVID-19 vaccines in record time, but let’s not be under any illusion about the profits that are motivating them.
Over nine months into COVID-19 outbreak in Nigeria, there are concerns about how well the country has managed the disease pandemic and how this might affect its handling of other diseases.
Health systems around the US are on the cusp of receiving COVID-19 vaccines. At the end of this months-long effort are the nitty-gritty details of how health care providers are giving people the vaccine.
Millions of Americans say they won’t get the vaccine. Will money change their minds? And is luring them with cash the right approach?
If the vaccine had been widely rolled out, people would think they had HIV when they didn’t. But it’s not the end of this type of technology.
Reports of two UK health workers having allergic reactions after receiving Pfizer’s COVID vaccine have led to safety warnings for others at risk of anaphylaxis.
Compared with other RNA viruses, the coronavirus is actually quite stable. So don’t believe the scary headlines about the ‘mutant coronavirus’.
New research shows why the N protein might be a good target.
The reason the vaccine appears to have worked better in participants who initially received only half a dose is still somewhat of a mystery.
Millions of Latinos may not get the influenza shot this year, which could be an indicator of whether they will get a COVID-19 shot. A rural clinic shows how building trust can help overcome reluctance.
At least three Chinese vaccines have been approved for emergency use, while phase 3 clinical trials are ongoing.
If supplies of COVID-19 vaccine are initially limited, who should be vaccinated first? A mathematical model shows when and why it’s best to start with the young, and when older people should go first.
Implausible theories give believers control over a puzzling and threatening world.
Here’s what you need to know about COVID-19 clearances before travelling.
Top contributors
-
Associate professor, UNSW Sydney
-
Associate Professor, Discipline of Childhood and Adolescent Health, University of Sydney
-
Early Career Research Leader, Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University
-
Paediatrician at the Royal Childrens Hospital and Associate Professor and Clinician Scientist, University of Melbourne and MCRI, Murdoch Children's Research Institute
-
Associate Professor, School of Social Sciences, The University of Western Australia
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Joel Lexchin is a Friend of The Conversation.
Professor Emeritus of Health Policy and Management, York University, Canada
-
Associate Professor, Epidemiology, Deakin University
-
Associate Professor, School of Biomedical Sciences and Pharmacy, University of Newcastle
-
Assistant Professor of Political Science, Oklahoma State University
-
Instructor of Human Immunology, Emory University
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Professor of Immunology, Vice-Chancellors Distinguished Professorial Fellow, Head of Immunology and Translational Research, Victoria University
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Chair in Epidemiology, Deakin University
